Literature DB >> 15570190

Validation of an assay for voriconazole in serum samples using liquid chromatography-tandem mass spectrometry.

Brian G Keevil1, Sheila Newman, Stephen Lockhart, Susan J Howard, Caroline B Moore, David W Denning.   

Abstract

A simple and rapid liquid chromatography tandem mass spectrometry (HPLC-MS/MS) method for the analysis of voriconazole has been developed. For comparison, serum voriconazole was measured using HPLC and bioassay. For the HPLC-MS/MS assay, samples were prepared in a deep-well block by adding 10 microL of serum to 40 microL of 0.1 M zinc sulfate solution. Proteins were precipitated by adding 100 microL acetonitrile containing ketoconazole as internal standard. After vigorous mixing and centrifugation, 3 microL of the supernatant was injected into the HPLC-MS/MS system. An HPLC system was used to elute a C18 cartridge (2 mm x 4 mm) at 0.6 mL/min with a step gradient of 50% to 100% methanol containing 2 mM ammonium acetate and 0.1% (vol/vol) formic acid. The column was maintained at 55 degrees C, and the retention times were voriconazole 1.50 minutes and ketoconazole 1.47 minutes. Cycle time was 3 minutes, injection to injection. The analytes were monitored using a tandem mass spectrometer operated in multiple reaction monitoring mode using the following transitions: voriconazole m/z 350.0 > 224.1 and ketoconazole m/z 531.1 > 489.1. Within- and between-batch CVs were < 5% and < 8%, respectively, over the range 0.38 to 15.3 mg/L. The lower limit of quantification was 0.1 mg/L. Regression analysis showed HPLC-MS/MS = 1.06 +/- 0.02 (HPLC-UV) - 0.07 +/- 0.1, R2 = 0.95, n = 99.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15570190     DOI: 10.1097/00007691-200412000-00011

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  11 in total

1.  Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin.

Authors:  Laurent Arthur Decosterd; Bertrand Rochat; Benoît Pesse; Thomas Mercier; Frédéric Tissot; Nicolas Widmer; Jacques Bille; Thierry Calandra; Boris Zanolari; Oscar Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2010-09-20       Impact factor: 5.191

2.  The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers.

Authors:  Guo Wang; He-Ping Lei; Zhi Li; Zhi-Rong Tan; Dong Guo; Lan Fan; Yao Chen; Dong-Li Hu; Dan Wang; Hong-Hao Zhou
Journal:  Eur J Clin Pharmacol       Date:  2008-11-04       Impact factor: 2.953

3.  Role of therapeutic drug monitoring of voriconazole in the treatment of invasive fungal infections.

Authors:  I Fan Kuo; Mary H H Ensom
Journal:  Can J Hosp Pharm       Date:  2009-11

4.  Validated LC Method for the Estimation of Voriconazole in Bulk and Formulation.

Authors:  C N Patel; J B Dave; J V Patel; B Panigrahi
Journal:  Indian J Pharm Sci       Date:  2009-11       Impact factor: 0.975

5.  Development and Validation of Stability Indicating RP-HPLC Method for Voriconazole.

Authors:  A B Khetre; P K Sinha; Mrinalini C Damle; R Mehendre
Journal:  Indian J Pharm Sci       Date:  2009-09       Impact factor: 0.975

6.  Development and Validation of Voriconazole Concentration by LC-MS-MS: Applied in Clinical Implementation.

Authors:  Santirat Prommas; Apichaya Puangpetch; Nuttawut Jenjirattithigarn; Sumonrat Chuwongwattana; Thawinee Jantararoungtong; Napatrupron Koomdee; Siwalee Santon; Montri Chamnanphon; Chonlaphat Sukasem
Journal:  J Clin Lab Anal       Date:  2016-06-24       Impact factor: 2.352

7.  Bioassay for Determining Voriconazole Serum Levels in Patients Receiving Combination Therapy with Echinocandins.

Authors:  Maria Siopi; Efthymios Neroutsos; Kalliopi Zisaki; Maria Gamaletsou; Maria Pirounaki; Panagiotis Tsirigotis; Nikolaos Sipsas; Aristides Dokoumetzidis; Evgenios Goussetis; Loukia Zerva; Georgia Valsami; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2015-10-26       Impact factor: 5.191

8.  Serum voriconazole level variability in patients with hematological malignancies receiving voriconazole therapy.

Authors:  Lalit Saini; Jack T Seki; Deepali Kumar; Eshetu G Atenafu; David Ec Cole; Betty Yl Wong; Andrea Božović; Joseph M Brandwein
Journal:  Can J Infect Dis Med Microbiol       Date:  2014-09       Impact factor: 2.471

9.  Clinical Impact of Cytochrome P450 2C19 Genotype on the Treatment of Invasive Aspergillosis under Routine Therapeutic Drug Monitoring of Voriconazole in a Korean Population.

Authors:  Si-Hyun Kim; Dong-Gun Lee; Jae-Cheol Kwon; Hyo-Jin Lee; Sung-Yeon Cho; Chulmin Park; Eun-Young Kwon; Sun Hee Park; Su-Mi Choi; Jung-Hyun Choi; Jin-Hong Yoo
Journal:  Infect Chemother       Date:  2013-12-27

10.  Breakthrough invasive fungal diseases during voriconazole treatment for aspergillosis: A 5-year retrospective cohort study.

Authors:  Sun Bean Kim; Sung-Yeon Cho; Dong-Gun Lee; Jae-Ki Choi; Hyo-Jin Lee; Si-Hyun Kim; Sun Hee Park; Su-Mi Choi; Jung-Hyun Choi; Jin-Hong Yoo; Jong-Wook Lee
Journal:  Med Mycol       Date:  2017-04-01       Impact factor: 4.076

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.